Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 7694

The 19 hospitalized patients from a single nursing home had tested positive for the virus in April.

All were older than age 64 and had chronic health conditions such as hypertension, dementia, heart disease, diabetes and lung diseases. Their age and health issues are considered risk factors for severe COVID-19.

The patients received either one or two intravenous doses of itolizumab along with the standard treatments used in Cuba at the time. Those included antiviral drugs, antibiotics, chloroquine, interferon, and blood thinners. Only two patients required oxygen therapy after the first dose, and all but one were discharged from the hospital in 14 days.

N”(Reuters) — An antibody drug already being used against the coronavirus in Cuba decreased the risk of intensive care admission and death among nursing home residents with moderate COVID-19, according to a small study conducted in the island nation.

India’s Biocon Ltd said earlier this month it received regulatory approval in India for itolizumab for use in coronavirus infected patients with moderate-to-severe respiratory distress. It was originally tested as a treatment for psoriasis.

Continue reading “Antibody drug lowers risk of death in elderly COVID-19 patients: Cuban study” | >

It would be heartening to think that cybersecurity has advanced since the 1990s, but some things never change. Vulnerabilities that some of us first saw in 1996 are still with us.

If you don’t believe me, just take a look at the news. Last month, Virginia-based cybersecurity firm GRIMM announced that they had found a vulnerability that affects many Netgear home WiFi routers. The cause? Outdated firmware that allows remote users to access the administrative systems in these routers.

If you think this exploit sounds like a 1990s-standard input overflow flaw, well done. That’s exactly what it is. As Nichols put it in his very detailed blog post: “1996 called, they want their vulnerability back.”

Read more | >

AMOLF researchers have presented a theory that describes the friction between biological filaments that are crosslinked by proteins. Surprisingly, their theory predicts that the friction force scales highly nonlinearly with the number of crosslinkers. The authors believe that cells use this scaling not only to stabilize cellular structures, but also to control their size. The new findings are important for the understanding of the dynamics of cellular structures such as the mitotic spindle, which pulls chromosomes apart during cell division.

Motor proteins versus frictional forces

Many consist of long filaments that are crosslinked by motor proteins and non-motor proteins (see figure). These so-called cytoskeletal structures not only give cells their mechanical stability, but also enable them to crawl over surfaces and to pull chromosome apart during . Force generation is typically attributed to motor proteins, which, using chemical fuel, can move the filaments with respect to one another. However, these motor forces are opposed by frictional forces that are generated by passive, non–. These frictional forces are a central determinant of the mechanical properties of cytoskeletal structures, and they limit the speed and efficiency with which these structures are formed. Moreover, they can even be vital for their stability, because if the motor forces are not opposed by the forces generated by the passive crosslinkers, the structures can even fall apart.

Read more | >

Tesla’s stock (TSLA) is surging 18% over the last few days as investors are getting in just before Battery Day and the important announcements that it will bring. On Wednesday, Tesla announced a 5 for 1 stock split that sent the stock price surging.

Despite stock splits not actually changing the value of a company, they have been known to increase stock prices temporarily as people anticipate higher volume from small investors.

Read more | >

NASA and SpaceX are targeting no earlier than Oct. 23 for the first operational flight with astronauts of the Crew Dragon spacecraft and Falcon 9 rocket to the International Space Station as a part of the agency’s Commercial Crew Program. NASA’s SpaceX Crew-1 mission will be the first of regular rotational missions to the space station following completion of NASA certification.

The mission will carry Crew Dragon commander Michael Hopkins, pilot Victor Glover, and mission specialist Shannon Walker, all of NASA, along with Japan Aerospace Exploration Agency (JAXA) mission specialist Soichi Noguchi for a six-month science mission aboard the orbiting laboratory following launch from Launch Complex 39A at NASA’s Kennedy Space Center in Florida.

Crew-1 will launch in late October to accommodate spacecraft traffic for the upcoming Soyuz crew rotation and best meet the needs of the International Space Station. Launch will follow the arrival of NASA astronaut Kate Rubins and cosmonauts Sergey Ryzhikov and Sergey Kud-Sverchkov of the Russian space agency Roscosmos aboard their Soyuz MS-17 spacecraft and the departure of NASA astronaut Chris Cassidy and cosmonauts Anatoly Ivanishin and Ivan Vagner from the space station. The launch timeframe also allows for a crew handover with NASA’s SpaceX Crew-2 mission next spring.

Read more | >

New research supported by the National Institutes of Health delineates how two relatively common variations in a gene called KIF3A are responsible for an impaired skin barrier that allows increased water loss from the skin, promoting the development of atopic dermatitis, commonly known as eczema. This finding could lead to genetic tests that empower parents and physicians to take steps to potentially protect vulnerable infants from developing atopic dermatitis and additional allergic diseases.

Atopic dermatitis is an that affects up to 20% of children in developed countries. This chronic is characterized by dry, thickened and intensely itchy skin, particularly in skin folds. People with eczema are more susceptible to bacterial, viral and fungal skin infections and frequently develop additional allergic diseases such as asthma.

KIF3A is a gene that codes for a protein involved in generating signals from the outside to the inside of a cell, part of a complex sensory apparatus. Previously, scientists had identified an association between two genetic variations in KIF3A and asthma in children who also had eczema. In the new study, the researchers found that these variations, or (SNPs), changed parts of the KIF3A gene to a form that can regulate, through a process called methylation, the rate at which a gene is transcribed into the blueprint for protein production. The investigators confirmed that skin and nasal-lining cells from people with the KIF3A SNP variants had more methylation and contained fewer blueprints for the KIF3A protein than cells in which KIF3A lacked the SNPs. In addition, the researchers demonstrated that people with the SNP-created regulating sites had higher levels of from the skin.

Read more | >